Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03006393 · ClinicalTrials.gov registry record · Phase 4
Dynamics of Inflammation and Its Blockade on Motivational Circuitry in Depression
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 42
- Enrollment target
NCT03006393 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 42 participants.
The verdict
NCT03006393, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 42 participants
- Enrollment target
Study Summary
The main purpose of this study is to examine the effects of infliximab on measures related to depression symptoms. Infliximab is also known by its brand name Remicade. Infliximab, or Remicade, is given to by an intravenous (IV) needle and is currently used to treat rheumatoid arthritis and Crohn's disease. Infliximab is thought to help these conditions because it reduces inflammation in the body. Infliximab (Remicade) reduces inflammation by blocking a chemical in the body called tumor necrosis factor (TNF)-alpha. This chemical produces inflammation. Inflammatory chemicals in the body like TNF-alpha appear to be increased in some people with major depression. Researchers believe that a drug like infliximab, which blocks TNF-alpha, may be helpful in treating depression. This is a double-blind, placebo-controlled study in which participants will be randomized to receive one infusion of infliximab or placebo. The study will assess neuroimaging measures of corticostriatal circuitry before and after a placebo-controlled pharmacologic blockade of inflammation in 80 depressed patients.
Interventions
- OTHER Placebo
- DRUG Infliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2016-08 |
| Est. Completion | 2020-09-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03006393
The ClinicalTrials.gov registry entry for NCT03006393 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03006393 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03006393 about?
NCT03006393 is a clinical study titled "Dynamics of Inflammation and Its Blockade on Motivational Circuitry in Depression". The main purpose of this study is to examine the effects of infliximab on measures related to depression symptoms. Infliximab is also known by its brand name Remicade. Infliximab, or Remicade, is given to by an intravenous (IV) needle and is currently used to treat rheumatoid arthritis and Crohn's d...
What is the current status of trial NCT03006393?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 42 participants. The study started on 2016-08. Estimated completion is 2020-09-26.
What interventions are being tested in trial NCT03006393?
The interventions under investigation include: Placebo (OTHER), Infliximab (DRUG).
Who is sponsoring clinical trial NCT03006393?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.